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Abstract
Background: Many studies have demonstrated that repeated injections of nicotine can produce progressive increases
in locomotor activity and enhanced expression of c-fos and tyrosine hydroxylase (TH) in brain dopaminergic areas.
Paecilomyces japonica (PJ) is a herbal medicine that is commonly used to treat opiate and other addictions in
Eastern Asia. However, its influence on nicotine addiction has not been examined. This study was carried out to
investigate the effects of PJ on repeated nicotine-induced behavioral sensitization of locomotor activity and c-Fos
and TH expression in the rat brain using immunohistochemistry.
Methods: Rats were pretreated with PJ (10, 25, 50, 100, and 200 mg/kg, intraperitoneally) 30 min before repeated
injections of nicotine (0.4 mg/kg, subcutaneously, twice daily for 7 days). Locomotor activity was measured in rats
during 7-day nicotine treatments. On the seventh day, c-Fos and TH expression were assessed.
Results: Pretreatment with PJ decreased the development of nicotine-induced sensitization, c-Fos expression in
the nucleus accumbens and striatum, and TH expression in the ventral tegmental area. PJ decreased nicotine-
induced locomotor activity by modulating brain dopaminergic systems.
Conclusion: The results of the present study suggest that PJ may be a useful agent for preventing and treating
nicotine addiction.
Keywords: Paecilomyces japonica (PJ), Nicotine, Locomotor activity, Development sensitization, c-Fos, Tyrosine
hydroxylase (TH), Dopamine
Background
Cigarette smoking has been related to many life-menacing
diseases including heart disease, cancer, and chronic
obstructive pulmonary disease [1]. The World Health
Organization reports that there are approximately 1.25
billion smokers worldwide at present and that global
mortality because of tobacco-related diseases will likely in-
crease from approximately five million deaths annually in
2004, to over ten million deaths per year in 2030 [2]. For
these reasons, cigarette smoking is a massive health prob-
lem in the world. Despite the many methods that have
been developed for smoking cessation [3, 4], abstaining
from smoking is difficult because of the addictive nature
of nicotine.
Nicotine is one of the major psychoactive ingredients in
tobacco and it is the principal addictive component of to-
bacco smoke, which contributes to the harmful tobacco
smoking habits [5]. Nicotine is a psychoactive drug affiliated
with diverse neurobiological and behavioral effects. It is an
agonist of nicotinic acetylcholine receptors [6]. Repeated
injection of the psychomotor stimulant drugs such as nico-
tine produces behavioral sensitization, a phenomenon evi-
denced by a steady increase in nicotine-induced behavioral
responses to repeated injections of nicotine [7]. The mecha-
nisms of behavioral sensitization have been suggested as an
animal model of drug addiction mainly associated with
repeated administration of psychomotor stimulant drugs,
and it has been implicated in the development of drug
addiction [8] and drug-induced psychosis [9, 10].
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The development of sensitization is defined as the tran-
sient sequence of cellular and molecular events brought
on by psychomotor stimulant administration that causes
lasting changes in neural function responsible for behav-
ioral augmentation [11], and has been connected anatom-
ically to the mesolimbic dopaminergic pathways [12].
Enhanced dopamine (DA) transmission in dopaminergic
target areas, including the nucleus accumbens (NAc) and
striatum, is thought to underlie the development of behav-
ioral sensitization to psychomotor stimulant drugs [13].
The behavioral sensitization caused by chronic injections
of psychomotor stimulants may be related to alterations of
neurotransmission in the mesolimbic dopaminergic path-
ways [14]. The cellular proto-oncogene c-fos belongs to
the immediate early gene family and its induction has
been used as a marker for postsynaptic activation [15].
Many neurons react to excitations of sufficient magnitude
and duration by expressing the proto-oncogene c-fos and
immunocytochemical detection of the Fos protein has
been used to map the neural circuitry acted on by a diver-
sity of behavioral and pharmacological treatments [16].
Several studies have suggested that administration of nico-
tine causes changes of the gene expression c-Fos in dopa-
minergic terminal regions, such as the NAc, striatum, and
prefrontal cortex [9].
Tyrosine hydroxylase (TH) is the rate-limiting enzyme
of DA synthesis in the midbrain dopaminergic neurons of
the ventral tegmental area (VTA) modulating locomotor
activity and reward. TH has been used as a marker for
biochemical changes induced by chronic psychomotor
stimulant exposure [17]. The levels of TH expression in
the VTA are regulated in response to the chronic adminis-
tration of several addictive drugs [18]. In addition, several
studies have shown that repeated administration of nico-
tine increases expression of TH and DA biosynthesis in
the mesolimbic DA pathway [19, 20].
Paecilomyces japonica (PJ) is one of the cordyceps species
and is artificially grown on silkworm larvae [21]. PJ has
been applied for medicinal purposes owing to its extensive
physiological activities [21]. In China, cordyceps has been
used as a remedy for more than 300 years. Many studies
have also reported that cordyceps includes antitumor
activity [22], immune-modulating effects [22], antioxi-
dant activity [23], anti-hyperglycemic activity [24], repro-
ductive function enhancement activity [25], anti-fatigue
activity [26], neurotrophic effects [27], and has a protective
effect on the kidney and liver [28]. Traditionally, cordyceps
has been used for centuries as a detoxification agent for
opioid addiction [29]. It has been used both in the treat-
ment of opioid addiction and for lead poisoning [30]. How-
ever, PJ has not yet been established to be effective for
nicotine addiction by experimental methods, even though
this is a likely effect of PJ considering the previous reports
on therapeutic effects of PJ in other addictive drugs.
This study was conducted to investigate the effects of
PJ on repeated nicotine-induced behavioral sensitization
and neuronal activity. The efficacy of PJ for nicotine-
induced behavioral and neural activation was investigated
by assessing locomotor activity and by using immunohis-
tochemical methods to determine a possible mechanism
underlying the suppressive effects of PJ on repeated-
nicotine-induced behavioral sensitization in rats.
Methods
Animals
The animals used in this study were 40 male Sprague–
Dawley rats, weighing 250 to 270 g at the start of the ex-
periment. Upon arrival, animals were randomly assigned to
several groups and housed for at least eight days prior to
experimental procedures. Rats were placed in a quiet,
temperature- and humidity-controlled room (23 °C ± 2 °C
and 60 % ± 5 %, respectively), and kept on a 12-h light, 12-h
dark cycle in individual home cages with food and water
available ad libitum. The current study was reviewed and
approved by the Ethics Committee of the Kyung Hee Uni-
versity (KHUASP (SE)-13-041) and their care conformed
to Guidelines of the US National Institutes of Health and
Korean Academy of Medical Sciences
Preparations of Paecilomyces japonica extract and drugs
Paecilomyces japonica (PJ) was purchased and identified
from the Plant Extract Bank (H Max Pharmacy Co, Daejon,
Korea). A voucher specimen of PJ has been deposited at the
herbarium located at the College of Korean Medicine,
Kyung Hee University (Reference No. KH-PJAM01). The
dried PJ (200 g) was drenched in 10-fold volume aqueous-
methanol (30:70) for 3 days on an ultrasound bath and
filtered through a muslin cloth and Whatman filter paper
(Maidstone, UK) concurrently. This process was repeated
three times and all the pooled filterates were evaporated
on a rotary evaporator (Eyela, Tokyo Rikakikai Co., Ltd.,
Japan), under reduced pressure (−760 mmHg) to get a
dark greenish semi-solid material, yielding 20.7 wt/wt %.
Animals and nicotine administration
Nicotine hydrogen tartrate was purchased from Sigma
Chemical (St. Louis, MO, USA). Nicotine was dissolved in
0.9 % saline at a concentration of 0.5 mg mL−1, and was
injected subcutaneously (s.c.) in a volume of 1 mL/1000 g.
Rats were randomly divided into seven groups. The de-
velopment of nicotine addiction was produced by repeated
injection of nicotine (0.4 mg/kg, s.c., free base equivalent)
twice a day for 7 consecutive days. The vehicle-treated rats
(as a negative control) were administered saline (0.9 %
NaCl, s.c.) instead of nicotine in the same way (normal
group). Another group was pretreated with PJ (10, 25, 50,
100, and 200 mg/kg, i.p. PJ group) intraperitoneally
30 min prior to the injection of saline in the development
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phase. The PJ-treated groups were divided as follows:
10 mg/kg PJ plus nicotine-treated group (PJ10 group),
25 mg/kg PJ plus nicotine-treated group (PJ25 group),
50 mg/kg PJ plus nicotine-treated group (PJ50 group),
100 mg/kg PJ plus nicotine-treated group (PJ100 group),
and 200 mg/kg PJ plus nicotine-treated group (PJ200
group). The PJ treatments were performed i.p. 30 min
prior to the injection of nicotine or saline.
Measurement of locomotor activity
Locomotor activity was measured by a contrast-sensitive
computer-controlled video tracking activity box in rats
during 7 day nicotine treatments. The system was com-
posed of a black ventilated test chamber (40 × 40 × 45),
interior lighted with a ceiling-mounted video camera. The
camera’s image was transmitted to a contrast-sensitive
tracker that mapped the point of highest contrast and
relayed the digitalized coordinates to a computer. Dedi-
cated software stored the information and coincidently dis-
played a map of the tracked subject. Data were collected in
10 min time bins during 1 h after all drug injections.
c-Fos and TH Immunohistochemistry
At the end of the locomotor session, animals were pro-
foundly anesthetized with sodium pentobarbital (100 mg/
kg, i.p), and then perfused transcardially with heparinized
0.9 % NaCl solution, followed by a 4 % solution of parafor-
maldehyde in 0.1 M phosphate-buffered saline (PBS;
pH 7.4) for 10–15 min. The brains were removed and
post-fixed in the same fixative for overnight. They were
then placed in 20 % sucrose solution diluted in 0.1 M so-
dium phosphate buffer (PBS; pH 7.4) for 2 days at 4 °C.
Brains were then frozen and coronal sections (30 μm
thick) were cut on the NAc, striatum, and VTA using
a cryostat (Leica CM1850; Leica Microsystems Ltd.,
Nussloch, Germany). The sections were obtained accord-
ing to the rat atlas of Paxinos and Watson (80). The sec-
tions were immunostained for Fos and TH protein
expression using the avidin-biotin-peroxidase method.
Briefly, the sections were rinsed three times for 3 min each
in PBS before being incubated in PBS containing 0.3 %
Triton X-100 (PBST) containing 0.02 sodium azide, 2 %
normal rabbit antibody or Fos primary antibody diluted
1:2000 (rabbit polyclonal antibody; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and 2 % normal sheep
antibody and TH primary antibody dilution 1:2000
(sheep polyclonal antibody; Chemicon International Inc.,
Temecular, CA, USA) for 72 h at 4 °C, respectively. After
three more rinses in PBST, the sections were placed in
Vectastain Elite ABC reagent (Vector Laboratories Ltd,
Burlingame, CA, USA) for 2 h at room temperature. To
visualize immunoreactivity, the sections were incubated
for 90 min in avidin-biotin complex (ABC) reagent
(Vectastain Elite ABC Kit; Vector Laboratories Ltd),
washed three times for 5 min in PBS, and incubated in a
solution containing 3,3'-diaminobenzidine (Sigma-Aldrich
Chemical Co., St. Louis, MO, USA) and 0.01 % H2O2 for
1 min. Finally, the tissues were washed in PBS and incuba-
tions were carried out in an orbital shaker, followed by a
brief rinse in distilled water, and individually mounted onto
slides. Slides were allowed to air dry, and were then cover
slipped. Images were captured using a DP2-BSW imaging
system (Olympus, CA, USA) and processed using Adobe
Photoshop (Adobe Systems, Inc., San Jose, CA, USA). The
sections were viewed at 100× magnification and the num-
ber of cells within 200 × 200 μm grids was counted by an
observer blinded to the experimental groups. The cells
within the NAc, striatum, and VTA were counted in at
least three different sections for each rat.
Statistical analysis
Statistical comparisons were conducted for the behav-
ioral and histochemical studies using one-way or
repeated-measures analysis of variance, respectively, and
Tukey’s post hoc tests were conducted. All of the results
are presented as means ± S.E.M., and we used SPSS 15.0
for Windows for analysis of the statistics. The signifi-
cance level was set at P < 0.05.
Results
Effects of PJ on Nicotine-Induced Behavioral Sensitization
The effects of PJ on repeated nicotine-induced hyperactivity
during the 7-day development phase are shown in Fig. 1. A
repeated-measures analysis of variance (7 × 8, treatment ×
time) performed on the locomotor activity following the PJ
treatments for the development test indicated a significant
effect of drug [F(6,40) = 28.240, p < 0.001], a significant
effect of time [F(7,42) = 3.964, p < 0.001], and a signifi-
cant interaction between drug × time [F(42,280) = 3.481,
p < 0.001]. The administration of PJ (10, 25, 50, and
100 mg/kg) before nicotine injection, during the 7 day de-
velopment phase, significantly inhibited the development
of nicotine-induced sensitization during the 7 day nicotine
treatments (Fig. 1). Tukey’s post-hoc comparisons indi-
cated that repeated injection of nicotine produced signifi-
cant increases in locomotor activity, compared with those
of saline-pretreated rats on day 7 (p < 0.001).
Effects of PJ on Nicotine-induced Fos-like Immunoreactivity
in the NAc and striatum
In rats receiving repeated nicotine, Fos-like immunoreac-
tivity (FLI) was increased, in a variety of brain areas.
Following the systemic injections of nicotine, a massive
amount of FLI was present in the NAc [F (6,83) = 88.451,
p < 0.001, Fig. 2]. In the NAc, post-hoc comparisons re-
vealed that the nicotine-treated group showed a marked
increase in the FLI compared with the saline-treated
group (P < 0.001, Fig. 2). Pretreatment with PJ (10, 25, 50,
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Fig. 1 Effects of PJ on nicotine-induced locomotor sensitization. Rats were pretreated with vehicle (▲), PJ (10 mg/kg, i.p.,▼ PJ10(dev)), PJ (25 mg/kg, i.p.,
◆ PJ25(dev)), PJ (50 mg/kg, i.p., ● PJ50(dev)), PJ (100 mg/kg, i.p., □ PJ100(dev)), or PJ (200 mg/kg, i.p., △ PJ200(dev)) 30 min before injections of nicotine twice
daily for 7 consecutive days. The saline-treated group was treated with only saline (■). * = significant difference from saline-treated, nicotine-treated group
and # from saline or PJ-pretreated and nicotine-treated group: *, P < 0.05; **, P< 0.01; ***, P< 0.001; #, P< 0.05; ##, P< 0.01; ###, P< 0.001. Vertical lines
indicate S.E.M. (N = 6–7)
Fig. 2 Expression of c-Fos in the NAc of rat brain after systemic injections of nicotine with PJ. Rats were pretreated with PJ (10, 25, 50, 100, 200 mg/kg)
30 min before nicotine injection (0.4 mg/kg). Expression of c-Fos in the NAc after systemic injections of saline, repeated nicotine or repeated nicotine
with PJ. Representative images are displayed (a). The scale bars represent 100 μm and 200 μm. The number of c-Fos cells in the NAc (b). * Significant
difference from saline-treated value (only shown for nicotine-treated) ***, P < 0.001, # Significant difference from nicotine-treated value ###, P < 0.001.
a; saline, b; nicotine, c; PJ10 + nicotine, d; PJ25 + nicotine, e; PJ50 + nicotine, f; PJ100 + nicotine, g; PJ200 + nicotine
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100, and 200 mg/kg) 30 min before the nicotine injection
decreased the numbers of Fos-like immunoreactive cells
to 24.25 ± 0.52 (p < 0.001), 19.08 ± 0.61 (p < 0.001), 11.5 ±
0.34 (p < 0.001), 11.75 ± 0.34 (p < 0.001), and 16.25 ± 0.53
(p < 0.001), respectively, as compared with Fos-like immu-
noreactive cells of 33.83 ± 1.71 in the nicotine-treated
group (Fig. 2).
In the striatum, post-hoc comparisons revealed that the
nicotine-treated group showed a marked increase in the
FLI compared with the saline-treated group [F(6,83) =
39.737, p < 0.001, Fig. 3]. Pretreatment with PJ (10, 25, 50,
100, and 200 mg/kg) 30 min before the nicotine injec-
tion decreased the numbers of Fos-like immunoreactive
cells to 9.92 ± 0.39 (p < 0.001), 7.75 ± 0.45 (p < 0.001),
5.5 ± 0.38 (p < 0.001), 5.41 ± 0.35 (p < 0.001), and 7.92 ±
0.42 (p < 0.001), respectively, as compared with Fos-like
immunoreactive cells of 21.58 ± 0.74 in the nicotine-
treated group (Fig. 3).
Effects of PJ on Nicotine-induced TH-like Immunoreactivity
in the VTA
Following the systemic injection of nicotine, a massive
amount of TH-like immunoreactivity was present in the
VTA of the nicotine-treated group, compared with the
saline-treated group. Nicotine-treated group immunoreac-
tivities were highly enriched in the VTA [F(6,83) = 15.598,
p < 0.001, Fig. 4]. This effect was significantly lessened by
PJ treatment during the development of sensitization. The
mean number of neurons showing TH-like immunoreac-
tivity in examined regions of the VTA was 21.58 ± 3.61
and 19.61 ± 2.72, for rats given repeated treatment. How-
ever, a much smaller number of immunoreactive cells
could be seen in these areas of the PJ-treated group. The
post-hoc comparisons revealed that the nicotine-treated
group showed a greater increase in TH expression than
the saline-treated group (p < 0.01). The administrations of
10, 25, 50, 100, and 200 mg/kg-body weight PJ, 30 min
before the nicotine injection, decreased the numbers of
TH-like immunoreactive cells to 27.39 ± 1.10 (p < 0.001),
22.83 ± 0.76 (p < 0.001), and 21.67 ± 0.75 (p < 0.001),
respectively, as compared with TH-like immunoreactive
cells of 29.56 ± 2.32 in the nicotine-treated group.
Discussion
In the present study, the effects of PJ on nicotine-induced
behavioral sensitization were compared, examined, and re-
lated to modulation of the activation of dopaminergic neu-
rons. The results show that pretreatment with PJ during
Fig. 3 Expression of c-Fos in the striatum of rat brain after systemic injections of nicotine with PJ. Expression of c-Fos in the striatum after systemic
injections of saline repeated nicotine with PJ. Representative images are displayed (a). The scale bars represent 100 μm and 200 μm. The number
of c-Fos cells in the striatum measured (b). * Significant difference from saline-treated value (only shown for nicotine-treated) ***, P < 0.001,
# Significant difference from nicotine-treated value ###, P < 0.001. a; saline, b; nicotine, c; PJ10 + nicotine, d; PJ25 + nicotine, e; PJ50 + nicotine,
f; PJ100 + nicotine, g; PJ200 + nicotine
Ye et al. BMC Complementary and Alternative Medicine  (2015) 15:227 Page 5 of 9
the development phase blocked the induction of behav-
ioral sensitization and expression of c-Fos and TH. PJ
is a codyceps species that is a well-known traditional
medicine. Our results suggest that PJ can block the
sensitization produced by repeated injections of addict-
ive drugs. PJ may be useful in treating or preventing
addiction-related behaviors and neural activity.
The results of this study demonstrate that repeated daily
administrations of nicotine produced a large increase in
locomotor activity. The present study also demonstrated
increased Fos-like immunoreactivity in the NAc and stri-
atum and TH-like immnoreactivity in the VTA, which are
the major projection areas of the dopaminergic system.
These results are concordant with previous findings [31].
The development of sensitization to psychomotor stim-
ulants leads to enduring changes in neural function
responsible for behavioral augmentation. A variety of
data sets show that these processes are functionally and
anatomically evident [11]. Several studies suggest that
different brain areas and different mechanisms are as-
sociated with the development of sensitization to psy-
chostimulant drugs such as nicotine [12]. Development
of behavioral sensitization to psychostimulants occurs
in the VTA [32, 33], which is the locus of the dopamine
cells that lead to the mesocorticolimbic dopamine
pathway [34]. Several studies have shown that the VTA
is related to the development phase of drug-induced
sensitization [14]. For example, intra-VTA injections of
SCH 23390 blocked both the cocaine-induced increase in
extracellular dopamine in the NAc and the development
of sensitized responses [35]. Furthermore, antagonists of
dopamine D1 and glutamate N-methyl-D-aspartate recep-
tors or agonists of GABAB receptors administered locally
in the VTA can arrest the development of amphetamine
sensitization [36]. These results suggest that the VTA is
related to the development of sensitization and the effects
of PJ during this development. The neural mechanisms by
which PJ is involved in nicotine-induced development of
sensitization remain to be fully elucidated.
Increased TH expression and dopamine release are
important factors in nicotine addiction [37]. Our find-
ings regarding expression of TH protein in the VTA
indicate a fine agreement with previous findings that
injection of nicotine elevates the extracellular DA
levels and its metabolites in the VTA [20, 38]. These
data suggest that pretreatment with PJ significantly
suppressed the nicotine-induced TH expression in the
VTA, suggesting that the suppressive effects of PJ are
related to blockade of dopaminergic biosynthesis or
transmission.
Fig. 4 Expression of TH in the VTA of rat brain after systemic injections of nicotine with PJ. Expression of TH in the VTA after systemic injections
of saline repeated nicotine or repeated nicotine with PJ. Representative images are displayed (a). The scale bars represent 100 μm. The number of
TH-positive neurons in the VTA (b). * Significant difference from saline-treated value (only shown for nicotine-treated) ***, P < 0.001, # Significant
difference from nicotine-treated value ##, P < 0.01; ###, P < 0.001. a; saline, b; nicotine, c; PJ10 + nicotine, d; PJ25 + nicotine, e; PJ50 + nicotine,
f; PJ100 + nicotine, g; PJ200 + nicotine
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Numerous studies have used c-fos expression mapping
approaches for the identification of neural circuits under-
lying behavioral sensitization to abused drugs [39].
The expression of c-Fos increases significantly in the
reward circuit-related areas after acute treatment with nico-
tine [40]. Previous studies have demonstrated that chronic
administration of nicotine induced the expression of
c-Fos in dopaminergic target areas, such as the NAc
and striatum [41], which are considered an important
region in the mediation of anticipatory and reward re-
sponses [42]. The induction of c-Fos protein in the
NAc and striatum indicated a fine agreement with the
previous findings that repeated injection of nicotine el-
evates the extracellular DA levels and its metabolites in
the NAc and striatum [20]. In the present study, effects
of PJ on nicotine-induced Fos-like immunoreactivity in
the NAc and striatum were compared with saline across
the development phase. We show that pretreatment with
PJ inhibits Fos-like immunoreactivity in the NAc and stri-
atum during the development of sensitization. These results
suggest that pretreatment with PJ may attenuate Fos-like
immunoreactivity by modulating the activities of postsyn-
aptic dopamine receptors in the NAc and striatum.
Cordyceps has a long history for use in drug abuse ther-
apy. Its therapeutic efficacy has been confirmed by many
medical studies in the Compendium of Materia Medica
(a compendium of Chinese Traditional medicines com-
plied by Li Shizhen). According to a recent study, cordy-
ceps are reported to have pro-recovery effects in severe
drug addicts as reported in a clinical trial in Switzerland.
The mechanism of PJ in drug abuse therapy has not been
investigated. In most cases, cordyceps are a type of trad-
itional Chinese tonic that has already shown a positive ef-
fect on some human body systems. Cordyceps have many
pharmacological ingredients, such as cordycepin, polysac-
charides, ergosterol and its analogs, mannitol, and pep-
tides [43]. A recent study has reported that mannitol
affects nicotine-induced neurotransmitter release [44].
Cordyceps have several bioactivities, such as aphrodisiac
[45, 46], analgesic [47], immune modulator [48], anti-
oxidant [49], antitumor [50], and antibacterial [51], and also
have protective effects on the kidney [50] and liver [28].
Furthermore, cordyceps have neurotrophic effects [27],
which have been found to modulate several addictive be-
haviors related to the actions of certain drugs of abuse [52].
Several studies show that neurotrophic factors and their
signaling pathways play an important role in mediating
drug-induced changes in brain reward systems and be-
havioral sensitization [53]. Consequently, pharmacological
compounds in cordyceps may be associated with neuro-
trophic effects, which regulate behavioral sensitization and
reward circuits of drug addiction. Despite this suggestion,
the effects of PJ concerning bioactivities and action mecha-
nisms have not yet been clearly analyzed. Additionally, in
neither study were there any reports of drug addiction re-
lated to PJ.
The present study showed that pretreatment with PJ dur-
ing the development phase also blocked the increased
locomotor activity to subsequent nicotine challenge. These
results are in good agreement with previous studies show-
ing that pretreatment with MK-801 and clozapine blocked
the development of sensitization to drugs of abuse such as
nicotine [54]. It is likely that the observed blockade of PJ
on behavioral activity is closely associated with the block-
ade of dopaminergic biosynthesis or transmission, shown
by reduced post-synaptic neuronal activation in dopamin-
ergic terminals, the Nac and striatum and pre-synaptic
neuronal activation in the VTA. These results suggest that
PJ could be effective for ameliorating the behavioral re-
sponses of nicotine dependence, possibly by modulating
the central dopaminergic system, and it may be a useful
therapeutic target for developing a novel drug for treating
nicotine addiction. However, more direct measures of be-
havioral sensitization, such as nicotine self-administration
or nicotine-induced conditioned place preference, should
be tested in the near future, to determine the inhibitory ef-
fects of PJ on nicotine-dependent behavioral patterns.
Conclusions
Paecilomyces japonica decreased the development of
nicotine-induced behavioral sensitization and c-Fos and
TH expression in the brain. PJ decreased the locomotor
activity of nicotine by possibly modulating the central
dopaminergic system, suggesting that PJ may be a use-
ful resource to develop as an agent for preventing and
treating nicotine addiction.
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